Home > In process > Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation. > print

001     285630
005     20260313130248.0
024 7 _ |a 10.1007/s00415-026-13718-z
|2 doi
024 7 _ |a pmid:41811373
|2 pmid
024 7 _ |a pmc:PMC12979338
|2 pmc
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
037 _ _ |a DZNE-2026-00269
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kassubek, Jan
|0 P:(DE-2719)9001967
|b 0
|u dzne
245 _ _ |a Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.
260 _ _ |a [Darmstadt]
|c 2026
|b Steinkopff
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1773403107_16829
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The hypothalamus as one of the core structures in metabolic control is increasingly recognized to be morphologically altered in various neurodegenerative diseases.The purpose of this study was to quantitatively investigate the hypothalamic volumes in patients with progressive supranuclear palsy (PSP) and to compare them with controls and Parkinson disease (PD) patients.An automatic hypothalamic volume quantification method based on the use of convolutional neural networks (CNN) of U-Net architecture was applied to the automatic segmentation of the hypothalamus and intracranial volumes (ICV). This CNN-based volumetric analysis was performed in high resolution T1 weighted MRI in two PSP cohorts: cohort A with 78 PSP patients and 63 controls was recorded at 3.0 T at multiple sites; the single site cohort B consisted of 66 PSP patients, 66 PD patients, and 44 controls, recorded at 1.5 T.In cohort A, significant hypothalamic volume reduction was observed in PSP (774 ± 83 mm3) when compared to controls (817 ± 74 mm3). In cohort B, this result of significant hypothalamic volume reduction was confirmed in PSP (745 ± 102 mm3) when compared to controls (831 ± 81 mm3); no significant hypothalamic volume reduction was observed in PD (797 ± 98 mm3), in support of previous studies.The CNN-based hypothalamus volume quantification study demonstrated significantly reduced hypothalamus volumes in PSP patients compared to controls and PD, respectively; future studies will address the metabolic profiles of PSP as potential functional correlates.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Hypothalamus
|2 Other
650 _ 7 |a Magnetic resonance imaging
|2 Other
650 _ 7 |a Metabolism
|2 Other
650 _ 7 |a Neural networks
|2 Other
650 _ 7 |a Progressive supranuclear palsy
|2 Other
650 _ 7 |a Volumetry
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnostic imaging
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: pathology
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: complications
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Hypothalamus: pathology
|2 MeSH
650 _ 2 |a Hypothalamus: diagnostic imaging
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neural Networks, Computer
|2 MeSH
650 _ 2 |a Atrophy: diagnostic imaging
|2 MeSH
650 _ 2 |a Atrophy: pathology
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Parkinson Disease: pathology
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Image Processing, Computer-Assisted: methods
|2 MeSH
650 _ 2 |a Convolutional Neural Networks
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DESCRIBE-PSP-20160101
|5 EXP:(DE-2719)DESCRIBE-PSP-20160101
|e DZNE Clinical Registry Study of Neurodegenerative Diseases in Patients with Progressive Supranuclear Paresis (PSP)
|x 0
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 1
|u dzne
700 1 _ |a Zůza, Adam
|b 2
700 1 _ |a Kreiser, Kornelia
|b 3
700 1 _ |a Roselli, Francesco
|0 P:(DE-2719)2812851
|b 4
|u dzne
700 1 _ |a Group, DESCRIBE-PSP Study
|b 5
|e Collaboration Author
700 1 _ |a Müller, Hans-Peter
|b 6
700 1 _ |a Brandt, Daniel Moritz
|0 P:(DE-2719)2812107
|b 7
|e Contributor
|u dzne
700 1 _ |a Bürger, Katharina
|0 P:(DE-2719)2811351
|b 8
|e Contributor
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 9
|e Contributor
|u dzne
700 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 10
|e Contributor
|u dzne
700 1 _ |a Flöel, Agnes
|0 P:(DE-2719)2812683
|b 11
|e Contributor
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 12
|e Contributor
|u dzne
700 1 _ |a Janowitz, Daniel
|0 P:(DE-2719)9002557
|b 13
|e Contributor
|u dzne
700 1 _ |a Katzdobler, Sabrina
|0 P:(DE-2719)9001160
|b 14
|e Contributor
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 15
|e Contributor
|u dzne
700 1 _ |a Kimmich, Okka
|0 P:(DE-2719)9002382
|b 16
|e Contributor
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 17
|e Contributor
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 18
|e Contributor
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 19
|e Contributor
|u dzne
700 1 _ |a Prudlo, Johannes
|0 P:(DE-2719)2380559
|b 20
|e Contributor
|u dzne
700 1 _ |a Schneider, Luisa-Sophie
|0 P:(DE-2719)9002878
|b 21
|e Contributor
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 22
|e Contributor
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 23
|e Contributor
|u dzne
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 24
|e Contributor
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 25
|e Contributor
|u dzne
700 1 _ |a Wilke, Carlo
|0 P:(DE-2719)2814101
|b 26
|e Contributor
|u dzne
773 _ _ |a 10.1007/s00415-026-13718-z
|g Vol. 273, no. 3, p. 201
|0 PERI:(DE-600)1421299-7
|n 3
|p 201
|t Journal of neurology
|v 273
|y 2026
|x 0367-004X
856 4 _ |u https://pub.dzne.de/record/285630/files/DZNE-2026-00269.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285630/files/DZNE-2026-00269.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9001967
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812851
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)2812107
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)2811351
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)2000005
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 10
|6 P:(DE-2719)2814178
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 11
|6 P:(DE-2719)2812683
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)2811614
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)9002557
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-2719)9001160
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-2719)2810394
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 16
|6 P:(DE-2719)9002382
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 17
|6 P:(DE-2719)2811659
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 19
|6 P:(DE-2719)2811122
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 20
|6 P:(DE-2719)2380559
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)9002878
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)2811324
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)2812446
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 24
|6 P:(DE-2719)2811275
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 25
|6 P:(DE-2719)2000026
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 26
|6 P:(DE-2719)2814101
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1910001
|k AG Roselli
|l Metabolic Changes in Neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1910001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21